Shigemasa Tani1,2, Ken Nagao3, Atsushi Hirayama3. 1. Department of Health Planning Center, Nihon University Hospital, 1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8309, Japan. tani.shigemasa@nihon-u.ac.jp. 2. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. tani.shigemasa@nihon-u.ac.jp. 3. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND AND OBJECTIVE: There is growing evidence of an association between high uric acid (UA) levels and cardiovascular disease (CVD). We hypothesized that febuxostat, a xanthine oxidase inhibitor, may be associated with suppressing the renin-angiotensin-aldosterone system (RAAS) and improving renal function in hyperurecemic patients with hypertension. METHODS: We conducted a 6-month prospective study in which we randomized hypertensive hyperuricemic patients to either a febuxostat group (n = 30) or a control group (n = 30). The dose of febuxostat was adjusted to maintain the serum UA level at <6.0 mg/dL. RESULTS: In the febuxostat group, the plasma renin activity (PRA), plasma aldosterone concentration (PAC), and serum UA level significantly decreased by 33 % (p = 0.0012), 14 % (p = 0.001), and 29 % (p < 0.0001), respectively. The estimated glomerular filtration rate (eGFR) significantly increased by 5.5 % (p = 0.001). Similar changes were not observed in the control group. Furthermore, a significant correlation was observed between the percent changes in the serum UA levels and the percent changes in the PRA (r = 0.277, p = 0.033), PAC (r = 0.310, p = 0.016), serum blood urea nitrogen levels (r = 0.434, p = 0.0005), serum creatinine levels (r = 0.413, p = 0.002), and eGFR (r = -0.474, p = 0.0001). CONCLUSIONS: These results support the hypothesis that febuxostat might not only reduce serum UA levels but also suppress RAAS and improve renal function in hyperuricemic patients with hypertension, possibly leading to prevention of CVD.
RCT Entities:
BACKGROUND AND OBJECTIVE: There is growing evidence of an association between high uric acid (UA) levels and cardiovascular disease (CVD). We hypothesized that febuxostat, a xanthine oxidase inhibitor, may be associated with suppressing the renin-angiotensin-aldosterone system (RAAS) and improving renal function in hyperurecemic patients with hypertension. METHODS: We conducted a 6-month prospective study in which we randomized hypertensive hyperuricemicpatients to either a febuxostat group (n = 30) or a control group (n = 30). The dose of febuxostat was adjusted to maintain the serum UA level at <6.0 mg/dL. RESULTS: In the febuxostat group, the plasma renin activity (PRA), plasma aldosterone concentration (PAC), and serum UA level significantly decreased by 33 % (p = 0.0012), 14 % (p = 0.001), and 29 % (p < 0.0001), respectively. The estimated glomerular filtration rate (eGFR) significantly increased by 5.5 % (p = 0.001). Similar changes were not observed in the control group. Furthermore, a significant correlation was observed between the percent changes in the serum UA levels and the percent changes in the PRA (r = 0.277, p = 0.033), PAC (r = 0.310, p = 0.016), serum blood ureanitrogen levels (r = 0.434, p = 0.0005), serum creatinine levels (r = 0.413, p = 0.002), and eGFR (r = -0.474, p = 0.0001). CONCLUSIONS: These results support the hypothesis that febuxostat might not only reduce serum UA levels but also suppress RAAS and improve renal function in hyperuricemicpatients with hypertension, possibly leading to prevention of CVD.
Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Umair Z Malik; Nicholas J Hundley; Guillermo Romero; Rafael Radi; Bruce A Freeman; Margaret M Tarpey; Eric E Kelley Journal: Free Radic Biol Med Date: 2011-04-15 Impact factor: 7.376
Authors: F Turnbull; B Neal; M Pfeffer; J Kostis; C Algert; M Woodward; J Chalmers; A Zanchetti; S MacMahon Journal: J Hypertens Date: 2007-05 Impact factor: 4.844
Authors: Anne E Nigra; Barbara V Howard; Jason G Umans; Lyle Best; Kevin A Francesconi; Walter Goessler; Richard Devereux; Ana Navas-Acien Journal: Environ Res Date: 2018-06-22 Impact factor: 6.498
Authors: Maryam Afkarian; Sarit Polsky; Afshin Parsa; Ronnie Aronson; Maria Luiza Caramori; David Z Cherney; Jill P Crandall; Ian H de Boer; Thomas G Elliott; Andrzej T Galecki; Allison B Goldfine; J Sonya Haw; Irl B Hirsch; Amy B Karger; Ildiko Lingvay; David M Maahs; Janet B McGill; Mark E Molitch; Bruce A Perkins; Rodica Pop-Busui; Marlon Pragnell; Sylvia E Rosas; Peter Rossing; Peter Senior; Ronald J Sigal; Catherine Spino; Katherine R Tuttle; Guillermo E Umpierrez; Amisha Wallia; Ruth S Weinstock; Chunyi Wu; Michael Mauer; Alessandro Doria Journal: Diabetes Care Date: 2019-06-11 Impact factor: 19.112
Authors: Yuka Sato; Daniel I Feig; Austin G Stack; Duk-Hee Kang; Miguel A Lanaspa; A Ahsan Ejaz; L Gabriela Sánchez-Lozada; Masanari Kuwabara; Claudio Borghi; Richard J Johnson Journal: Nat Rev Nephrol Date: 2019-07-11 Impact factor: 28.314
Authors: Laura G Sanchez-Lozada; Bernardo Rodriguez-Iturbe; Eric E Kelley; Takahiko Nakagawa; Magdalena Madero; Dan I Feig; Claudio Borghi; Federica Piani; Gabriel Cara-Fuentes; Petter Bjornstad; Miguel A Lanaspa; Richard J Johnson Journal: Am J Hypertens Date: 2020-07-18 Impact factor: 3.080